Skip to content

Discovery and Biological Characterization of Potent MEK inhibitors in melanoma

MEK inhibitor

Although sample size was small, the two dose cohorts demonstrated comparable anti-tumor activity

Posted on January 20, 2022 By scienzaunder18

Although sample size was small, the two dose cohorts demonstrated comparable anti-tumor activity. abnormal hepatic function and coagulation tests, and upper gastrointestinal hemorrhage. The most common treatment-related adverse events were proteinuria, hypertension and diarrhea. Among 34 patients receiving sulfatinib formulation 2, one patient with hepatocellular carcinoma and eight with neuroendocrine tumors exhibited a partial response; 15 had stable disease. The objective response rate was 26.5% (9/34) and the disease control rate was 70.6% (24/34). Pharmacokinetic, safety, and efficacy data supported continuous oral administration of sulfatinib at 300 mg as the recommended phase II dose. Sulfatinib exhibited an acceptable safety profile and encouraging antitumor activity in patients with advanced solid tumors, particularly neuroendocrine tumors. strong class=”kwd-title” Keywords: phase I clinical trial, neuroendocrine tumor, solid tumor, sulfatinib, tyrosine kinase inhibitor INTRODUCTION Vascular endothelial growth factor (VEGF)- and fibroblast growth factor (FGF)-mediated pathways play key roles in tumor angiogenesis [1, 2]. VEGF and FGF secretion by tumor cells promotes rapid proliferation and packing of endothelial cells, which leads to the formation of excessive, coarsely packed blood vessels [3]. These blood vessels supply oxygen and nutrients to the tumor and promote tumor cell leakage into the circulation, resulting in increased tumor growth and a risk of metastasis [3]. While VEGF receptor (VEGFR)-targeted therapies are important in the management of several cancer types, many patients exhibit no or limited respond to treatment, due in part to tumor cell resistance through alternative molecular pathways [4]. In response to anti-VEGF therapies, some tumors can increase FGF secretion to stimulate endothelial cell proliferation, promote tumor angiogenesis, and bypass VEGF signaling pathways [4, 5]. Evidence also suggests that VEGFR, FGF receptors (FGFRs), and colony stimulating factor 1 receptor (CSF1R) promote tumor immune evasion. VEGF secreted by tumors can activate VEGFR signaling pathways in T cells; this leads to programmed cell death protein 1 (PD-1) receptor overexpression, which decreases T cell anti-tumor activity [6]. FGFR and CSF1R also appear to induce tumor-associated macrophage proliferation and differentiation, thereby promoting tumor immune evasion [7]. Targeting multiple kinases to simultaneously block VEGFR-, FGFR-, and CSF1R-mediated pathways may be a more effective method of preventing tumor angiogenesis and tumor immune evasion, and therefore represents an attractive anti-cancer therapy approach. Sulfatinib (HMPL012) is a potent small molecule tyrosine kinase inhibitor of VEGFR 1, 2, and 3, FGFR 1, and CSF1R [8], and has demonstrated selectivity in a broad kinase screening (Table ?(Table1).1). The aims of this phase I clinical CUDC-101 study in patients with advanced solid tumors were to determine the sulfatinib maximum tolerated dose (MTD) and recommended dose for further phase II investigations. The study was designed to investigate the safety, pharmacokinetics (PK), and tumor response of sulfatinib. Table 1 Sulfatinib kinase selectivity profile thead th align=”left” valign=”middle” rowspan=”1″ colspan=”1″ Kinase /th th align=”center” valign=”middle” rowspan=”1″ colspan=”1″ IC50 (M) /th /thead VEGFR Rabbit polyclonal to Dcp1a 10.002VEGFR 20.024VEGFR 30.001FGFR10.015CSF1R0.004TrkB0.041FLT30.067278 other kinases 0.150 Open in a separate window FLT3: fms-related tyrosine kinase 3; IC50: half maximal inhibitory concentration; TrkB: tropomyosin receptor kinase B. RESULTS Patient baseline characteristics Seventy-seven Chinese patients were enrolled in 12 dose cohorts between April 2010 and September 2014, and followed up until July 2015 (Figure ?(Figure1).1). The first 43 patients received sulfatinib formulation 1 and the remaining 34 received formulation 2 (Figure ?(Figure2).2). Patient baseline demographic and clinical characteristics are summarized in Table ?Table22. Open in a separate window Figure 1 Study designaSulfatinib dose was escalated (until MTD was met) according to a modified Fibonacci 3+3 protocol. Each patient received the assigned dose for the study duration. CUDC-101 bThe tumor expansion phase was initiated following determination of the recommended phase II dose based on the results of the dose-escalation phase. Open in a separate window Figure 2 Patient configurationaAt enrolment, patients were assigned a dose sequentially according to the Fibonacci 3+3 dose-escalation design. Patients received that dose for the study duration. bPatients who completed the DLT observation phase could remain on treatment at their original dose until disease progression or any other withdrawal criteria were met. Table 2 Patient baseline demographic and clinical characteristics thead th align=”left” valign=”top” rowspan=”1″ colspan=”1″ Characteristic /th th align=”center” valign=”top” rowspan=”1″ colspan=”1″ Formulation 1 (N=43) /th th align=”center” valign=”top” rowspan=”1″ colspan=”1″ Formulation 2 (N=34) /th /thead CUDC-101 Median (range) age, years52.7 (23.5C69.9)56.0 (23.4C73.2)Gender, n (%)?Male27 (62.8)24 (70.6)?Female16 (37.2)10 (29.4)Tumor type, n (%)?Colorectal carcinoma9 (20.9)0?Hepatocellular carcinoma8 (18.6)9 (26.5)?Stromal tumor8 (18.6)1 (2.9)?NET (grade 1/2)a7 (16.3)21 (61.8)?Non-small cell lung cancer2 (4.7)0?Renal cell carcinoma2 (4.7)0?Other7 (16.3)3 (8.8)ECOG performance status, n (%)?010 (23.3)4 (11.8)?129 (67.4)30 (88.2)?24 (9.3)0Median (range) time since diagnosis,.

Urotensin-II Receptor

Post navigation

Previous Post: Comparisons between the Ever sick leave versus the Never sick leave groups were undertaken using the Wilcoxon test for continuous variables (skewed distribution) and either the 2 2 or Fishers exact test for categorical variables
Next Post: bc-GenExMiner 3

More Related Articles

However, when a double C3aR/C5aR KO EAE mice model was generated, a delayed onset but a similar course of disease was seen (Ramos et al Urotensin-II Receptor
This low degree of protein aggregation could be because of the fact that in today’s study we used marketed products within their original formulation and primary container, whereas the cited studies were done on noncommercial IgG molecules Urotensin-II Receptor
After PM2 Urotensin-II Receptor
Interestingly, AMD3100 can be an agonist for ACKR3 also, and therefore serve simply because both an antagonist and an agonist for just two molecules from the same pathway (223) Urotensin-II Receptor
In order to examine, whether both or only one polysialyltransferase is expressed in HUVEC, the presence of the respective mRNA was tested Urotensin-II Receptor
shots of LISP-A10 (Process 1) Urotensin-II Receptor

Archives

  • June 2025
  • May 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • October 2024
  • September 2024
  • May 2023
  • April 2023
  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021

Categories

  • Acetylcholine ??7 Nicotinic Receptors
  • Acetylcholine Nicotinic Receptors
  • Acyltransferases
  • ALK Receptors
  • Alpha1 Adrenergic Receptors
  • Angiotensin Receptors, Non-Selective
  • cMET
  • COX
  • CYP
  • Cytochrome P450
  • Decarboxylases
  • FFA1 Receptors
  • GABAA and GABAC Receptors
  • GlyR
  • H1 Receptors
  • HDACs
  • Hexokinase
  • IGF Receptors
  • K+ Ionophore
  • L-Type Calcium Channels
  • LXR-like Receptors
  • Metastin Receptor
  • Miscellaneous Glutamate
  • Neurokinin Receptors
  • Nicotinic Acid Receptors
  • Nitric Oxide, Other
  • Nucleoside Transporters
  • Opioid, ??-
  • Oxidative Phosphorylation
  • Oxytocin Receptors
  • PDK1
  • PI 3-Kinase
  • Potassium (KV) Channels
  • Potassium Channels, Non-selective
  • Prostanoid Receptors
  • Protein Kinase B
  • Protein Ser/Thr Phosphatases
  • PTP
  • Retinoid X Receptors
  • Serotonin (5-ht1E) Receptors
  • Sigma1 Receptors
  • Sirtuin
  • Syk Kinase
  • T-Type Calcium Channels
  • Transient Receptor Potential Channels
  • TRPP
  • Uncategorized
  • Urotensin-II Receptor
  • Vesicular Monoamine Transporters
  • VIP Receptors
  • XIAP

Recent Posts

  • Arterial blood circulation pressure was measured using a pressure transducer (Statham P23 ID, Gould, Cleveland, OH, USA) linked to the arterial catheter
  • As NK cell priming will be the total consequence of multiple cytokines, than looking to stop one cytokine rather, blocking the pathways which derive from the binding of cytokines on the receptors which talk about the normal c chain could be more appropriate
  • Subfigures (AD) display data of one representative donor out of three independent experiments
  • Seventy four percent from the seropositive health care workers from Circular 1 returned for antibody evaluation
  • Almost all ofS

Recent Comments

  1. A WordPress Commenter on Hello world!

Copyright © 2025 Discovery and Biological Characterization of Potent MEK inhibitors in melanoma.

Powered by PressBook Blog WordPress theme